{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05477563",
            "orgStudyIdInfo": {
                "id": "VX21-CTX001-161"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-006390-37",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Vertex Pharmaceuticals Incorporated",
                "class": "INDUSTRY"
            },
            "briefTitle": "Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent \u03b2-Thalassemia and Severe Sickle Cell Disease",
            "officialTitle": "A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent \u03b2-Thalassemia or Severe Sickle Cell Disease",
            "therapeuticArea": [
                "Rare Diseases",
                "Other"
            ],
            "study": "evaluation-of-efficacy-and-safety-of-a-single-dose-of-in-participants-with-transfusion-dependent-thalassemia-and-severe-sickle-cell-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-26",
            "studyFirstSubmitQcDate": "2022-07-26",
            "studyFirstPostDateStruct": {
                "date": "2022-07-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vertex Pharmaceuticals Incorporated",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "CRISPR Therapeutics",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single-dose, open-label study in participants with transfusion-dependent \u03b2-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001."
        },
        "conditionsModule": {
            "conditions": [
                "Beta-Thalassemia",
                "Thalassemia",
                "Hematologic Diseases",
                "Genetic Diseases, Inborn",
                "Hemoglobinopathies",
                "Sickle Cell Anemia",
                "Sickle Cell Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 26,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CTX001",
                    "type": "EXPERIMENTAL",
                    "description": "CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.",
                    "interventionNames": [
                        "Biological: CTX001"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "CTX001",
                    "description": "Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.",
                    "armGroupLabels": [
                        "CTX001"
                    ],
                    "otherNames": [
                        "Exagamglogene autotemcel",
                        "Exa-cel"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Fetal Hemoglobin (HbF) Concentration Over Time",
                    "timeFrame": "Up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "Total Hemoglobin (Hb) Concentration Over Time",
                    "timeFrame": "Up to 12 Months After CTX001 Infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "TDT and SCD: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "timeFrame": "From Signing of Informed Consent up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Proportion of Participants With Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count (ANC) >=500 per Microliter [mcgL] on 3 Different Days)",
                    "timeFrame": "Within 42 Days After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Time to Engraftment",
                    "timeFrame": "Up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Incidence of Transplant-Related Mortality (TRM) Within 100 Days After CTX001 Infusion",
                    "timeFrame": "Within 100 Days After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Incidence of TRM Within 12 Months After CTX001 Infusion",
                    "timeFrame": "Within 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Incidence of All-cause Mortality",
                    "timeFrame": "From Signing of Informed Consent up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Relative Reduction in Annualized Volume of RBC Transfusions",
                    "timeFrame": "From Day 60 up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Proportion of Alleles With Intended Genetic Modification Present in Peripheral Blood Over Time",
                    "timeFrame": "Up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "TDT and SCD: Proportion of Alleles With Intended Genetic Modification Present in CD34+ Cells of the Bone Marrow Over Time",
                    "timeFrame": "Up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "TDT: Duration Transfusion Free in Participants",
                    "timeFrame": "Up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "SCD: Relative Reduction in Annualized Rate of Severe Vaso-Occlusive Crises (VOCs)",
                    "timeFrame": "From Baseline up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "SCD: Relative Reduction in Annualized Rate of Inpatient Hospitalizations for Severe VOCs",
                    "timeFrame": "From Baseline up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "SCD: Relative Reduction in Annualized Duration of Hospitalization for Severe VOCs",
                    "timeFrame": "From Baseline up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "SCD: Relative Reduction in Haptoglobin",
                    "timeFrame": "From Baseline up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "SCD: Relative Reduction in Lactate dehydrogenase",
                    "timeFrame": "From Baseline up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "SCD: Relative Reduction in Total Bilirubin",
                    "timeFrame": "From Baseline up to 12 Months After CTX001 Infusion"
                },
                {
                    "measure": "SCD: Relative Reduction in Indirect Bilirubin",
                    "timeFrame": "From Baseline up to 12 Months After CTX001 Infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Participants with TDT and SCD:\n\n  * Eligible for autologous stem cell transplant as per investigator's judgment.\n* Participants with TDT:\n\n  * Diagnosis of TDT as defined by:\n\n    * Documented homozygous \u03b2-thalassemia or compound heterozygous \u03b2-thalassemia including \u03b2-thalassemia/hemoglobin E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning\n    * History of at least 100 milliliter (mL)/kilograms (kg)/year or 10 units/year of packed red blood cells (RBC) transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening\n* Participants with SCD:\n\n  * Diagnosis of severe SCD as defined by:\n\n    * Documented SCD genotypes\n    * History of at least two severe VOCs events per year for the previous two years prior to enrollment\n\nKey Exclusion Criteria:\n\n* Participants with TDT and SCD:\n\n  * A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor is available per investigator's judgement\n  * Prior hematopoietic stem cell transplant (HSCT)\n  * Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator\n* Participants with TDT:\n\n  * Participants with associated \u03b1-thalassemia and \\>1 alpha deletion, or alpha multiplications\n  * Participants with sickle cell \u03b2-thalassemia variant\n* Participants with SCD:\n\n  * History of untreated moyamoya syndrome or presence of moyamoya syndrome at screening\n\nOther protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "maximumAge": "35 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Medical Information",
                    "role": "CONTACT",
                    "phone": "617-341-6777",
                    "email": "medicalinfo@vrtx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Columbia University Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Atrium Health Levine Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "SCRI at the Children's Hospital at TriStar Centennial",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum D\u00fcsseldorf Hospital Duesseldorf",
                    "status": "RECRUITING",
                    "city": "Duesseldorf",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.22172,
                        "lon": 6.77616
                    }
                },
                {
                    "facility": "Ospedale Pediatrico Bambino Ges\u00f9, IRCCS",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Rome",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "King Faisal Specialist Hospital and Research Centre",
                    "status": "RECRUITING",
                    "city": "Al Mathar Ash Shamali",
                    "country": "Saudi Arabia"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000755",
                    "term": "Anemia, Sickle Cell"
                },
                {
                    "id": "D000013789",
                    "term": "Thalassemia"
                },
                {
                    "id": "D000017086",
                    "term": "beta-Thalassemia"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006453",
                    "term": "Hemoglobinopathies"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000745",
                    "term": "Anemia, Hemolytic, Congenital"
                },
                {
                    "id": "D000000743",
                    "term": "Anemia, Hemolytic"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4085",
                    "name": "Anemia, Sickle Cell",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M16557",
                    "name": "Thalassemia",
                    "asFound": "Thalassemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19408",
                    "name": "beta-Thalassemia",
                    "asFound": "Beta Thalassemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "asFound": "Genetic Diseases, Inborn",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "asFound": "Hematologic Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9539",
                    "name": "Hemoglobinopathies",
                    "asFound": "Hemoglobinopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4073",
                    "name": "Anemia, Hemolytic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4075",
                    "name": "Anemia, Hemolytic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "T5622",
                    "name": "Thalassemia",
                    "asFound": "Thalassemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T737",
                    "name": "Beta-thalassemia",
                    "asFound": "Beta Thalassemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5229",
                    "name": "Sickle Cell Anemia",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M5336",
                    "name": "Busulfan",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}